Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
PHASE3CompletedINTERVENTIONAL
Enrollment
46
Participants
Timeline
Start Date
March 31, 2015
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
Conditions
Cystic FibrosisAdvanced Lung Disease
Interventions
DRUG
Lumacaftor
DRUG
Ivacaftor
Trial Locations (6)
Unknown
Denver
Tampa
Chicago
St Louis
Pittsburgh
Houston
All Listed Sponsors
lead
Vertex Pharmaceuticals Incorporated
INDUSTRY
NCT02390219 - Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease | Biotech Hunter | Biotech Hunter